Pub. Date : 2006 Dec
PMID : 17138749
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression). | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | kinase insert domain receptor | Homo sapiens |
| 2 | Small-animal PET revealed rapid, specific, and prominent uptake of (64)Cu-DOTA-VEGF(121) in small U87MG tumors (high VEGFR2 expression) but significantly lower and sporadic uptake in large U87MG tumors (low VEGFR2 expression). | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | kinase insert domain receptor | Homo sapiens |
| 3 | Blocking experiments, immunofluorescence staining, and western blot confirmed the VEGFR specificity of (64)Cu-DOTA-VEGF(121). | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | kinase insert domain receptor | Homo sapiens |
| 4 | CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy. | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | kinase insert domain receptor | Homo sapiens |
| 5 | CONCLUSION: Successful demonstration of the ability of (64)Cu-DOTA-VEGF(121) to visualize VEGFR expression in vivo may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and guiding antiangiogenic treatment, especially patient selection and treatment monitoring of VEGFR-targeted cancer therapy. | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid | kinase insert domain receptor | Homo sapiens |